RAPT Therapeutics, Inc. - Common Stock (NQ:RAPT)

57.61 +0.04 (+0.07%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 21, 2026 Add to My Watchlist

Price and Volume

Volume	1,891,994
Open	57.54
Bid (Size)	57.50 (500)
Ask (Size)	58.00 (100)
Prev. Close	57.57
Today's Range	57.54 - 57.62
52wk Range	5.666 - 57.62
Shares Outstanding	34,358,152
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT

Today 16:48 EST

From Kahn Swick & Foti, LLC

Via Business Wire

Why Rapt Therapeutics Stock Soared Today ↗

January 20, 2026

A global healthcare giant wants to acquire the biotech's promising development program.

Via The Motley Fool

Performance

YTD	+80.9%	+80.9%
1 Month	+58.0%	+58.0%
3 Month	+92.0%	+92.0%
6 Month	+313.3%	+313.3%
1 Year	+500.1%	+500.1%

More News

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RAPT Therapeutics, Inc. (Nasdaq – RAPT), Penumbra, Inc. (NYSE – PEN), Calavo Growers, Inc. (Nasdaq – CVGW), FONAR Corporation (Nasdaq - FONR)

January 20, 2026

From Brodsky & Smith LLC

Via GlobeNewswire

Here are the top movers in Tuesday's session. ↗

January 20, 2026

Via Chartmill

Tuesday's session: top gainers and losers ↗

January 20, 2026

Via Chartmill

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

January 20, 2026

Via Chartmill

GSK Challenges Xolair Dominance with $2.2 Billion Acquisition of RAPT Therapeutics

January 20, 2026

Via MarketMinute

Wondering what's happening in today's pre-market session? ↗

January 20, 2026

Via Chartmill

RAPT Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of RAPT Therapeutics, Inc. is Fair to Shareholders

January 20, 2026

From Halper Sadeh LLC

Via Business Wire

Why Did RAPT Stock Surge 63% In Pre-Market Today? ↗

January 20, 2026

Via Stocktwits

RAPT Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 07, 2026

From RAPT Therapeutics, Inc.

Via GlobeNewswire

This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits ↗

December 29, 2025

Via The Motley Fool

Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally

November 07, 2025

Via MarketMinute

RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

November 06, 2025

From RAPT Therapeutics, Inc.

Via GlobeNewswire

RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences

November 04, 2025

From RAPT Therapeutics, Inc.

Via GlobeNewswire

RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies

October 27, 2025

From RAPT Therapeutics, Inc.

Via GlobeNewswire

RAPT Therapeutics Announces Pricing of Public Offering of Common Stock

October 21, 2025

From RAPT Therapeutics, Inc.

Via GlobeNewswire

RAPT Therapeutics Announces Proposed Public Offering of Common Stock

October 21, 2025

From RAPT Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's Intraday Session ↗

October 20, 2025

Via Benzinga

Rapt Therapeutics, Outperforming 98% Of All Stocks, Skyrockets After Topping Roche ↗

October 20, 2025

Via Investor's Business Daily

These stocks are moving in today's pre-market session ↗

October 20, 2025

Via Chartmill

RAPT Therapeutics and Shanghai Jeyou Pharmaceutical Announce Positive Topline Data from Phase 2 Trial of RPT904 (JYB1904) in Chronic Spontaneous Urticaria

October 20, 2025

From RAPT Therapeutics, Inc.

Via GlobeNewswire

Why Delcath Systems Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket ↗

October 20, 2025

Via Benzinga

RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy

September 29, 2025

From RAPT Therapeutics, Inc.

Via GlobeNewswire

RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)

October 19, 2025

From RAPT Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is RAPT Therapeutics, Inc. - Common Stock publicly traded?

Yes, RAPT Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does RAPT Therapeutics, Inc. - Common Stock trade on?

RAPT Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for RAPT Therapeutics, Inc. - Common Stock?

The ticker symbol for RAPT Therapeutics, Inc. - Common Stock is RAPT on the Nasdaq Stock Market

What is the current price of RAPT Therapeutics, Inc. - Common Stock?

The current price of RAPT Therapeutics, Inc. - Common Stock is 57.61

When was RAPT Therapeutics, Inc. - Common Stock last traded?

The last trade of RAPT Therapeutics, Inc. - Common Stock was at 01/21/26 04:00 PM ET

What is the market capitalization of RAPT Therapeutics, Inc. - Common Stock?

The market capitalization of RAPT Therapeutics, Inc. - Common Stock is 1.98B

How many shares of RAPT Therapeutics, Inc. - Common Stock are outstanding?

RAPT Therapeutics, Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.